Hip Replacement Devices MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy MaterialBy Fixation TechniqueBy Age Group

Hip replacement devices are the implant systems, comprising femoral stems, acetabular cups, femoral heads and liners in various bearing-surface materials, that surgeons use to replace a damaged or worn hip joint. They are used in primary procedures for patients with degenerative joint disease, partial procedures that resurface only part of the joint, and revision procedures that replace a previously implanted device that has failed or worn out. Buyers are hospitals, ambulatory surgical centers and the orthopedic surgeons and procurement teams within them who select implant systems through direct purchase, tender or group-purchasing arrangements.

Between 2025 and 2034 the global hip replacement devices market hip replacement devices market moves from USD 8.1 billion to USD 13.8 billion, compounding at 6.24% a year. Fifteen years are covered in all, taking in USD 6.35 billion in 2020, USD 7.78 billion in 2024, USD 8.5 billion in 2026 and USD 10.81 billion in 2030.

Composition changes more than the total does. Revision HIP Replacement, at 8.47%, outgrows Primary HIP Replacement at 5.44%, and its share moves from 13% to 15.7%. Primary HIP Replacement stays the largest line throughout, at USD 5.5485 billion in 2025 and USD 8.832 billion in 2034. Share moves toward Partial HIP Replacement, Revision HIP Replacement and HIP Resurfacing and away from Primary HIP Replacement, though no line shrinks in revenue terms.

The application split puts Hospitals first, at USD 6.318 billion and 78% of revenue in 2025, rising to USD 9.936 billion and 72% in 2034. Ambulatory Surgical Centers grows faster at 8.98% against 5.16%, moving from 22% of revenue to 28% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

Geographically, 45% of 2025 revenue sits in North America (USD 3.645 billion rising to USD 5.7132 billion) ahead of Europe at 24% and USD 1.944 billion. Middle East and Africa is smallest, at 4%. Because Asia Pacific take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Behind these figures sit five regions, four type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 8.1 billion in 2025 to USD 13.8 billion in 2034, a compound annual rate of 6.24%, having reached USD 7.78 billion in 2024 from USD 6.35 billion in 2020.
• The largest line by type is Primary HIP Replacement, worth USD 5.5485 billion and 68.5% of revenue in 2025, rising to USD 8.832 billion and 64% by 2034.
• Fastest growth on the type axis belongs to Revision HIP Replacement: 8.47% a year, USD 1.053 billion to USD 2.1666 billion, and a share moving from 13% to 15.7%.
• Against a base case of USD 13.8 billion in 2034, the study also reports a bear case at USD 12.7 billion and a bull case at USD 14.9 billion, with the assumptions behind each set out separately.
• The largest region is North America, generating USD 3.645 billion in 2025 (45% of the global total) and USD 5.7132 billion by 2034, ahead of Europe at 24%.
• The United States accounts for 87% of North America in the base year, worth USD 3.171 billion in 2025 and reaching USD 4.971 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Read across the forecast period, the global hip replacement devices market hip replacement devices market shows movement in three places: type composition, regional weight, and the 6.24% rate applied to the whole.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Revision HIP Replacement grows faster than Primary HIP Replacement. Revision HIP Replacement grows at 8.47% across 2026-2034 against 5.44% for Primary HIP Replacement, the widest spread on the type axis. Shares follow: 13% to 15.7% for Revision HIP Replacement, 68.5% to 64% for Primary HIP Replacement. Revenue rises on both sides; USD 1.053 billion to USD 2.1666 billion and USD 5.5485 billion to USD 8.832 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

The regional balance moves. Asia Pacific moves from 22% of revenue in 2025 to 27.4% in 2034, worth USD 1.782 billion rising to USD 3.7812 billion. The remaining regions grow in absolute terms while giving up share: North America at 45% moving to 41.4%, Europe at 24% moving to 22.2%, Latin America at 5% moving to 5%, Middle East and Africa at 4% moving to 4%. That makes the regional split worth reading rather than scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

A continuation, not an inflection. Fifteen years of revenue run USD 6.35 billion in 2020, USD 7.78 billion in 2024, USD 8.1 billion in 2025, USD 8.5 billion in 2026, USD 10.81 billion in 2030 and USD 13.8 billion in 2034. There is no discontinuity to time, and 6.24% forecast growth against 4.99% historical means the trend continues rather than turns. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Revision HIP Replacement adds the most incremental growth

Growth in the global hip replacement devices market hip replacement devices market comes from three measurable sources over 2026-2034: the market's own compounding at 6.24%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.

Downside case: USD 12.7 billion rather than USD 13.8 billion by 2034

Upside case: USD 14.9 billion by 2034

The total depends on a single line

45% of the global hip replacement devices market hip replacement devices market sits in North America in 2025, worth USD 3.645 billion rising to USD 5.7132 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 41.4% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The type mix reported at global level applies here, with Primary HIP Replacement the largest line at 68.5% of 2025 revenue and Revision HIP Replacement the fastest-growing at 8.47%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

87% of North America's base-year revenue comes from the United States; USD 3.171 billion, rising to USD 4.971 billion by 2034. 87% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Regional revenue of USD 3.645 billion in 2025 and USD 5.7132 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The type pattern in the United States is the global one: 68.5% of 2025 revenue in Primary HIP Replacement, 64% by 2034, against 8.47% growth in Revision HIP Replacement taking it from 13% to 15.7%. Its 87% weight in North America means those movements carry straight into the regional totals. Per-type revenue for the United States appears on its own in the full report.

In the United States, hip replacement devices are regulated by the Food and Drug Administration as Class III implantable devices given their permanent, load-bearing role in the body. Most systems reach the market through the premarket approval pathway, which requires clinical evidence of safety and effectiveness, though some component modifications may qualify for a premarket notification route when substantial equivalence to a predicate device can be shown. Manufacturers must comply with the Quality System Regulation covering design controls and production, maintain traceability through a Unique Device Identification system, and meet FDA labelling requirements disclosing indications, materials, and implantation instructions.

Competition in the United States runs between the suppliers this study tracks: Zimmer, Smith & Nephew, DePuy Synthes, Waldemar LINK, Stryker, Corin, B. Braun, Medacta International, MicroPort Orthopedics, Exactech, Enovis, Limacorporate and Meril Life Sciences. The commercially relevant division is 68.5% of 2025 revenue in Primary HIP Replacement, where the volume is, against 8.47% growth in Revision HIP Replacement, where share moves. The full report covers country-level positioning and shares company by company; this summary does not.

Within North America, Canada accounts for 13% of regional revenue and 5.9% of the global total, worth USD 0.474 billion in 2025 and USD 0.743 billion by 2034.

Europe holds 24% of the global hip replacement devices market hip replacement devices market in 2025, worth USD 1.944 billion and reaches USD 3.0636 billion by 2034. Among the five regions it ranks second by revenue in both years.

Its share moves to 22.2% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Primary HIP Replacement largest at 68.5% of 2025 revenue, Revision HIP Replacement fastest at 8.47%. The full report breaks Europe out along every axis and by country.

USD 0.583 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 0.919 billion by 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 1.944 billion in 2025 and USD 3.0636 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Primary HIP Replacement at 68.5% of 2025 revenue, easing to 64% by 2034, and the fastest is Revision HIP Replacement at 8.47%, from 13% to 15.7%. Its 30% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.

In Germany, hip replacement devices fall under the EU Medical Device Regulation, which classifies implantable joint replacements as Class III products subject to the highest level of scrutiny. Manufacturers must undergo conformity assessment through a Notified Body, encompassing technical documentation review, clinical evaluation, and quality management system audits aligned with the harmonised European standard for medical device manufacturing. A successful assessment permits the affixing of the CE mark, and devices must be registered in the EUDAMED database with a unique device identifier. German labelling rules further require instructions and safety information in the national language alongside the manufacturer's declaration of conformity.

In Germany the field is Zimmer, Smith & Nephew, DePuy Synthes, Waldemar LINK, Stryker, Corin, B. Braun, Medacta International, MicroPort Orthopedics, Exactech, Enovis, Limacorporate and Meril Life Sciences. Two different problems sit on the same axis: holding Primary HIP Replacement at 68.5% of 2025 revenue, and taking Revision HIP Replacement while it grows at 8.47%.

France is sized at USD 0.428 billion in 2025, rising to USD 0.674 billion by 2034; 5.3% of global revenue and 22% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, the United Kingdom accounts for 20% of regional revenue and 4.8% of the global total, worth USD 0.389 billion in 2025 and USD 0.613 billion by 2034.

USD 1.782 billion of 2025 revenue is generated in Asia Pacific, 22% of the global hip replacement devices market hip replacement devices market on the way to USD 3.7812 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Share climbs to 27.4% by 2034, at a pace above the 6.24% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Within the region the type split tracks the global one; 68.5% of 2025 revenue in Primary HIP Replacement, fastest growth of 8.47% in Revision HIP Replacement. Asia Pacific is reported axis by axis and country by country in the full study.

China is the largest market within Asia Pacific, generating USD 0.677 billion in 2025 and projected to reach USD 1.361 billion by 2034. At 38% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 1.782 billion to USD 3.7812 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Primary HIP Replacement at 68.5% of 2025 revenue, easing to 64% by 2034, and the fastest is Revision HIP Replacement at 8.47%, from 13% to 15.7%. Since 38% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for China appears on its own in the full report.

In China, hip replacement devices are regulated by the National Medical Products Administration, which classifies implantable joint prostheses under its highest-risk device category due to their permanent, load-bearing function. Domestic and overseas manufacturers must obtain a medical device registration certificate, supported by clinical trial data generated within the country or accepted through recognised bilateral arrangements, before commercial distribution is permitted. Products must conform to applicable national medical device standards covering biocompatibility, mechanical performance, and sterilisation, and packaging must carry Chinese-language labelling detailing intended use, materials, and handling precautions. Manufacturing sites are subject to periodic quality system inspections by provincial authorities.

Competition in China runs between the suppliers this study tracks: Zimmer, Smith & Nephew, DePuy Synthes, Waldemar LINK, Stryker, Corin, B. Braun, Medacta International, MicroPort Orthopedics, Exactech, Enovis, Limacorporate and Meril Life Sciences. Volume sits in Primary HIP Replacement at 68.5% of 2025 revenue; movement sits in Revision HIP Replacement at 8.47% growth.

Japan is sized at USD 0.463 billion in 2025, rising to USD 0.832 billion by 2034; 5.7% of global revenue and 26% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Within Asia Pacific, India accounts for 14% of regional revenue and 3.1% of the global total, worth USD 0.249 billion in 2025 and USD 0.681 billion by 2034.

Latin America holds 5% of the global hip replacement devices market hip replacement devices market in 2025, worth USD 0.405 billion rising to USD 0.69 billion in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 5% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The type mix reported at global level applies here, with Primary HIP Replacement the largest line at 68.5% of 2025 revenue and Revision HIP Replacement the fastest-growing at 8.47%. Per-axis and per-country detail for Latin America sits in the full report.

55% of Latin America's base-year revenue comes from Brazil; USD 0.223 billion, rising to USD 0.38 billion by 2034. It accounts for 55% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 0.405 billion in 2025 and USD 0.69 billion in 2034, it is the country the full report breaks out in detail.

Demand in Brazil follows the type mix reported at global level: Primary HIP Replacement is the largest line at 68.5% of 2025 revenue, moving to 64% by 2034, while Revision HIP Replacement grows fastest at 8.47% and takes its share from 13% to 15.7%. With 55% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for Brazil appears on its own in the full report.

In Brazil, hip replacement devices are overseen by ANVISA, the national health surveillance agency, which classifies implantable orthopaedic prostheses as high-risk products requiring formal marketing authorisation before sale. Manufacturers, whether domestic or foreign, must register the device and demonstrate compliance with Good Manufacturing Practices through facility certification, alongside technical dossiers covering material composition, sterilisation validation, and clinical performance. Portuguese-language labelling stating indications, contraindications, and traceability information is mandatory, and post-market vigilance reporting obligations apply once the device is in commercial use. A locally established or represented manufacturer is generally required to interface with the regulator.

In Brazil the field is Zimmer, Smith & Nephew, DePuy Synthes, Waldemar LINK, Stryker, Corin, B. Braun, Medacta International, MicroPort Orthopedics, Exactech, Enovis, Limacorporate and Meril Life Sciences. Volume sits in Primary HIP Replacement at 68.5% of 2025 revenue; movement sits in Revision HIP Replacement at 8.47% growth.

Mexico is sized at USD 0.122 billion in 2025, rising to USD 0.207 billion by 2034; 1.5% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

USD 0.324 billion of 2025 revenue is generated in Middle East and Africa, 4% of the global hip replacement devices market hip replacement devices market and reaches USD 0.552 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

4% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Primary HIP Replacement leads here as it does globally, at 68.5% of 2025 revenue, and Revision HIP Replacement again grows fastest at 8.47%. The full report breaks Middle East and Africa out along every axis and by country.

40% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.13 billion, rising to USD 0.221 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.324 billion to USD 0.552 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Saudi Arabia follows the type mix reported at global level: Primary HIP Replacement is the largest line at 68.5% of 2025 revenue, moving to 64% by 2034, while Revision HIP Replacement grows fastest at 8.47% and takes its share from 13% to 15.7%. Its 40% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-type revenue for Saudi Arabia appears on its own in the full report.

In Saudi Arabia, hip replacement devices are regulated by the Saudi Food and Drug Authority under its medical device framework, which follows internationally harmonised risk-classification principles and places implantable joint prostheses in its highest-risk category. Manufacturers must obtain a medical device marketing authorisation before commercial distribution, supported by evidence of conformity with recognised international quality and safety standards and, where applicable, prior approval from a reference regulatory authority. Establishment licensing for local distributors and importers is required, along with Arabic-language labelling covering intended use and handling instructions, and adverse event reporting obligations continue once the device is placed on the market.

The suppliers tracked in this study (Zimmer, Smith & Nephew, DePuy Synthes, Waldemar LINK, Stryker, Corin, B. Braun, Medacta International, MicroPort Orthopedics, Exactech, Enovis, Limacorporate and Meril Life Sciences) compete in Saudi Arabia across the type lines above. Two different problems sit on the same axis: holding Primary HIP Replacement at 68.5% of 2025 revenue, and taking Revision HIP Replacement while it grows at 8.47%.

South Africa is sized at USD 0.081 billion in 2025, rising to USD 0.138 billion by 2034; 1% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Material, Fixation Technique, Age Group, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.